Correlation Between Spyre Therapeutics and QVC

Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and QVC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and QVC into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Spyre Therapeutics and QVC Group, you can compare the effects of market volatilities on Spyre Therapeutics and QVC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of QVC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and QVC.

Diversification Opportunities for Spyre Therapeutics and QVC

-0.61

Correlation Coefficient

Spyre Therapeutics  QVC

Excellent diversification

The 3 months correlation between Spyre and QVC is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and QVC Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on QVC Group and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with QVC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of QVC Group has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and QVC go up and down completely randomly.

Pair Corralation between Spyre Therapeutics and QVC

Given the investment horizon of 90 days Spyre Therapeutics is expected to generate 1.38 times more return on investment than QVC. However, Spyre Therapeutics is 1.38 times more volatile than QVC Group. It trades about 0.06 of its potential returns per unit of risk. QVC Group is currently generating about -0.55 per unit of risk. If you would invest  1,576  in Spyre Therapeutics on May 4, 2025 and sell it today you would earn a total of  50.00  from holding Spyre Therapeutics or generate 3.17% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	95.45%
Values	Daily Returns

Spyre Therapeutics  vs.  QVC Group

Spyre Therapeutics

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Spyre Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Spyre Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

QVC Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days QVC Group has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain relatively invariable which may send shares a bit higher in September 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Spyre Therapeutics and QVC

The main advantage of trading using opposite Spyre Therapeutics and QVC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, QVC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in QVC will offset losses from the drop in QVC's long position.

The idea behind Spyre Therapeutics and QVC Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.